皮下注射免疫球蛋白治疗重症肌无力轻度至中度加重:一项前瞻性开放标签试验
这项前瞻性、开放标签、3期试验纳入23例年龄≥18岁、轻度至中度加重的重症肌无力患者,给予皮下注射免疫球蛋白(SCIg)2 g/kg,4周内自行给药。主要终点为6周时定量MG(QMG)评分较基线的变化。结论认为SCIg在轻度至中度MG加重中耐受良好、安全有效,但需随机对照试验确立比较安全性和有效性。
要点
- SCIg 2 g/kg在4周内自行给药,可显著降低轻度至中度MG加重患者的QMG评分。
- MMT、MG-ADL和MGC评分均显著改善,患者治疗满意度高。
- 常见不良事件为头痛和注射部位反应,无严重不良事件。
核心结论
- SCIg在轻度至中度重症肌无力加重患者中耐受良好、安全且有效,可降低MG残疾指标。
- 需要随机对照试验确立SCIg与其他治疗的比较安全性和有效性。
研究设计与样本
- 前瞻性、开放标签、3期试验,纳入23例年龄≥18岁、轻度至中度加重的重症肌无力患者。
- SCIg 2 g/kg在4周内自行给药,主要终点为6周时QMG评分较基线的变化。
主要发现
- QMG评分从14.9±4.1降至9.8±5.6(p<0.0001)。
- MMT评分从16.8±9.5降至5.2±4.5(p<0.0001)。
- MG-ADL评分从9.5±3.0降至4.6±3.0(p<0.0001)。
- MGC评分从17.4±5.0降至5.6±4.5(p<0.0001)。
关键数值与推荐
- TSQM满意度高(79.6±15.6%)。
- 常见不良事件包括头痛和注射部位反应,无严重不良事件。
- 证据等级为Class IV,表明SCIg在轻度至中度MG加重中安全有效。
临床怎么用
- 对于轻度至中度加重的重症肌无力患者,可考虑使用SCIg 2 g/kg在4周内自行给药。
- 治疗期间应监测QMG、MMT、MG-ADL和MGC评分以评估疗效。
- 需注意头痛和注射部位反应等常见不良事件。
局限性
- 开放标签设计可能引入偏倚。
- 样本量较小(23例)。
- 缺乏随机对照比较,需进一步随机对照试验确认比较安全性和有效性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To investigate the efficacy, tolerability, and safety of subcutaneous immunoglobulin (SCIg) in patients with mild to moderate myasthenia gravis (MG) exacerbation. METHODS: We performed a prospective, open-label, phase 3 trial in patients with MG aged 18 years or older and mild to moderate worsening (transition from Myasthenia Gravis Foundation of America class I to II/III or class II to III), treated with SCIg (2 g/kg), self-administered over 4 weeks. The primary endpoint was change in quantitative MG (QMG) score from baseline to study end at 6 weeks. Secondary endpoints included change in manual muscle testing (MMT), MG activities of daily living (MG-ADL), and MG composite (MGC) scores, as well as occurrence of adverse events, and tolerability as assessed via Treatment Satisfaction Questionnaire for Medication (TSQM). RESULTS: Twenty-two of 23 patients completed the study. QMG score decreased from 14.9 ± 4.1 to 9.8 ± 5.6 (p < 0.0001), MMT score decreased from 16.8 ± 9.5 to 5.2 ± 4.5 (p < 0.0001), MG-ADL score decreased from 9.5 ± 3.0 to 4.6 ± 3.0 (p < 0.0001), and MGC score decreased from 17.4 ± 5.0 to 5.6 ± 4.5 (p < 0.0001). Satisfaction by TSQM was high (79.6 ± 15.6%). Common adverse events included headache and injection site reactions. No serious adverse events occurred. CONCLUSIONS: SCIg is well-tolerated, safe, and effective in mild to moderate MG exacerbation. Comparative safety and efficacy must be established with randomized controlled trials. CLASSIFICATION OF EVIDENCE: This study provides Class IV evidence that in patients with mild to moderate MG exacerbation, SCIg is safe and effective in reducing MG disability measures.
引用
- Beecher G, Anderson D, Siddiqi ZA, et al. Subcutaneous immunoglobulin in myasthenia gravis exacerbation: A prospective, open-label trial. Neurology. 2017. PMID: 28814461. doi:10.1212/WNL.0000000000004365
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。